NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GENESA (arbutamine hydrochloride) is an injectable small-molecule cardiac stress agent approved in 1997 for diagnostic use in cardiovascular testing. It is a synthetic catecholamine that mimics the effects of exercise on the heart, enabling non-invasive assessment of cardiac function and coronary perfusion in patients unable to undergo physical stress testing.
LOE Approaching
Product is in late-lifecycle stage with moderate competitive pressure (30/100), suggesting a consolidated, defensive team focused on maintaining existing accounts rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GENESA currently shows zero linked job openings, reflecting its mature, stable commercial footprint with limited growth initiatives. Career opportunities on this product are primarily tactical—focused on account retention, relationship management, and operational efficiency in a declining-market environment.
Brand ManagerField Sales Representative
Worked on GENESA at AutoMedicus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.